510(k) device
Elecsys Troponin T Gen 5
Roche Diagnostics · Immunoassay Method, Troponin Subunit (MMI, Class II) · First FDA decision May 17, 2004, newest Sep 21, 2021Heart attack (myocardial infarction)Heart attack and heart failure blood tests
Last checked: Nov 21, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
510(k) pathway
Device trials
2
Naming "Elecsys"
MAUDE reports
7,859
Brand "Elecsys", since 2015
PubMed studies
1,828
Mentioning "Elecsys"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Elecsys Troponin T Gen 5
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- Elecsys Troponin T Gen 5510(k)
K201441 · Decided Sep 21, 2021 · 477 days after receipt
Device type: Immunoassay Method, Troponin Subunit (MMI) · Laboratory Medicine & Pathology
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Elecsys", any status and sponsor, newest update first.
Dragonfly Research, LLCAcademic, hospital or other
NCT04837651 · 48 participants · Start Mar 2, 2021 · Primary completion Jul 1, 2021
Device: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test; T-Detect COVID T-cell blood test · For: Multiple Sclerosis; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System and 5 more
Sites: Wellesley, Massachusetts
1 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Elecsys", and for the whole product code for context.
This brand
7,859 reports: 7,766 malfunction, 61 injury, 0 death
Whole product code MMI
7,546 reports: 7,009 malfunction, 528 injury, 4 death
Newest reports for this brand
- Elecsys Folate IIIMalfunction
1823260-2026-04537 · Received Oct 30, 2026 · Event dated Oct 6, 2026
Device type: Acid, Folic, Radioimmunoassay (CGN)
Device problem as coded: Incorrect Measurement
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Elecsys Troponin I STAT Immunoassay: Catalog# 05094798160 - Product Usage: intended to aid in the diagnosis of myocardial infarction.Open, Classified
Roche Diagnostics Operations, Inc.
Z-1595-2021 · Started Apr 7, 2021
Reason given: Recall reason is possible sporadic false negative conventional troponin results. Roche has confirmed an issue with running Elecsys Troponin I/Troponin I STAT and Elecsys proBNP II/proBNP II STAT on the cobas e 601 and 602 modules. When the proBNP II analyte is measured immediately before the Troponin I analyte on the...
Cause as FDA categorized it: Device Design · Device type: Immunoassay Method, Troponin Subunit (MMI)
4 more recall records with a free account
Published research
The most relevant PubMed records for "Elecsys"[tiab]. The summary above synthesizes these.
- Drugs for dementia.
Med Lett Drugs Ther · 2026
- Humoral Immune Response to SARS-CoV-2.
Herroelen PH, Martens GA, De Smet D, et al. · Am J Clin Pathol · 2020Research Support, Non-U.S. Gov't
- Elecsys pTau217 plasma immunoassay detection of amyloid pathology in clinical cohorts.
Hibar DP, Bauer A, Rabe C, et al. · Alzheimers Dement · 2026
- Elecsys Cerebrospinal Fluid Immunoassays Accurately Detect Alzheimer's Disease Regardless of Concomitant Small Vessel Disease.
Ortner M, Lanz K, Goldhardt O, et al. · J Alzheimers Dis · 2023Research Support, Non-U.S. Gov't
- Elecsys CSF AD immunoassays: Sample stability for a new pre-analytical protocol for fresh CSF.
Manuilova E, Schrurs I, Rutz S, et al. · Alzheimers Dement · 2025
- Clinical Application Evaluation of Elecsys® HIV Duo Assay in Southwest China.
Yang M, Yang W, Shi W, et al. · Front Cell Infect Microbiol · 2022
- Sensitivity of the Elecsys Nucleocapsid Assay for the Detection of Preceding SARS-CoV-2 Infections.
Grunau B, Tom J, Asamoah-Boaheng M, et al. · Open Forum Infect Dis · 2022
- Clinical performance of the Roche Elecsys SARS-CoV-2 antigen fully automated electrochemiluminescence immunoassay.
Salvagno GL, Pighi L, De Nitto S, et al. · Pract Lab Med · 2022
- Utility of Roche Elecsys anti-SARS-CoV-2 S in ascertaining post-vaccine neutralizing antibodies.
Aijaz J, Kanani F, Naseer F · J Clin Virol Plus · 2023
- Multicenter performance evaluation of the Elecsys HCV Duo immunoassay.
Majchrzak M, Bronner K, Laperche S, et al. · J Clin Virol · 2022Multicenter Study, Research Support, Non-U.S. Gov't
- Elecsys® AMH assay: Determination of Anti-Müllerian hormone levels and evaluation of the relationship between superovulation response in Holstein dairy cows.
Koca D, Aktar A, Turgut AO, et al. · Vet Med Sci · 2024Research Support, Non-U.S. Gov't
- Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease.
Blennow K, Stomrud E, Zetterberg H, et al. · Clin Chem Lab Med · 2023
Other devices of this type
Also filed under product code MMI.
- Access hsTnIBeckman Coulter, Inc. · 510(k) 2025
- i-STAT hs-TnI cartridge with the i-STAT Alinity SystemAbbott Point of Care, Inc. · 510(k) 2026
- VITROS Immunodiagnostic Products hs Troponin I Reagent PackOrtho-Clinical Diagnostics, Inc. · 510(k) 2025
- Atellica® IM High-Sensitivity Troponin I (TnIH)Siemens Healthcare Diagnostics, Inc. · 510(k) 2024
- Alinity i STAT High Sensitivity Troponin-IAbbott Laboratories Diagnostics Division · 510(k) 2023
- Vidas Troponin I Ultra (Tniu) Assay, Model 30 448bioMerieux, Inc. · 510(k) 2007
- Dimension Vista Ctni Flex Reagent CartridgeDade Behring, Inc. · 510(k) 2007
- Abbott Axsym Troponin-I AdvAbbott Laboratories · 510(k) 2006
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.